Guardant Health Adds Dexcom's Kevin Sayer To Its Board, Raising It To 11 Seats
Sayer, Dexcom's former CEO, takes a Class II seat, and Guardant also named Robert Parks its chief accounting officer.
Guardant Health, which makes blood and tissue tests for cancer, expanded its board to 11 directors and seated Kevin Sayer, the former CEO of Dexcom, the company said Tuesday. The board also named Robert Parks as chief accounting officer, according to an 8-K filing.
A Dexcom veteran joins the board
Sayer, 68, took a Class II seat effective November 2, with a term running to the 2029 annual meeting of stockholders. He is Dexcom's executive chairman, a post he has held since January 1, 2026, and ran the company as president and CEO from January 2015 to January 2026.
Before Dexcom, he was chief financial officer of Biosensors International Group, and held executive roles at Specialty Laboratories and MiniMed. He is an inactive certified public accountant with degrees from Brigham Young University.
His pay follows the standard non-employee director program: a restricted stock unit award valued at $500,000 and a $60,000 annual cash retainer. One-third of the award vests on the first anniversary of his appointment, and the rest on each of the next two anniversaries, provided he keeps serving.
Sayer said Guardant's liquid biopsy leadership puts it in a "powerful position to shape the next era of cancer care and disease detection," according to the press release. Chairman and co-CEO Helmy Eltoukhy said Sayer has a record of "delivering significant growth."
A new chief accounting officer
Parks, 54, was appointed November 2 and has taken on the role of principal accounting officer. He was chief accounting officer at clinical research firm Fortrea Holdings from August 2024 to August 2026.
Before that he held the same title at SailPoint Technologies from September 2023 to August 2024, at NetApp from 2021 to September 2023, and at Syneos Health from 2018 to 2021. From 2011 to 2018 he worked at IQVIA, including as senior vice president, corporate controller and principal accounting officer. He began at Ernst & Young and is a CPA.
He will receive a base salary, an annual bonus opportunity and restricted stock unit awards under the company's 2023 Employment Inducement Award Plan.
Where Guardant stands in cancer testing
Guardant's Guardant360 tests help pick treatments for advanced cancer, its Reveal test looks for residual and recurring disease in early-stage colorectal, breast and lung cancer, and its Shield blood test screens average-risk adults 45 and older for colorectal cancer. It sells to oncologists, cancer centers and primary care physicians, and to drugmakers that use its data in drug development.
Sayer's seat comes up for a stockholder vote at the 2029 annual meeting.
Sources
- 8-K Filing — Guardant Health, Inc. (GH) — SEC EDGAR
- Exhibit d173393dex991.htm — Guardant Health, Inc. 8-K exhibit — SEC EDGAR